229920001296 polysiloxane Polymers 0.000 claims description 2.210000004165 Myocardium Anatomy 0.000 claims description 2.230000002439 hemostatic Effects 0.000 claims description 3. 210000003540 Papillary Muscles Anatomy 0.000 claims description 3.210000003516 Pericardium Anatomy 0.000 claims description 4.210000004115 Mitral Valve Anatomy 0.000 claims description 4. 239000000463 material Substances 0.000 claims description 6.230000000004 hemodynamic Effects 0.000 claims description 6.238000004321 preservation Methods 0.000 claims description 7.210000000115 Thoracic Cavity Anatomy 0.000 claims description 7.210000001308 Heart Ventricles Anatomy 0.000 claims description 13.230000000875 corresponding Effects 0.000 claims description 24.239000002473 artificial blood Substances 0.000 claims description 64.230000003387 muscular Effects 0.000 claims abstract description 4.210000001370 Mediastinum Anatomy 0.000 claims abstract description 7.Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) Filing date Publication date Priority to UY26.289 priority Critical Priority to UY26289A priority patent/UY26289A1/en Application filed by Giambruno Marono Juan Manuel filed Critical Giambruno Marono Juan Manuel Publication of WO2002011789A1 publication Critical patent/WO2002011789A1/en Links Inventor Juan Manuel GIAMBRUNO MAROÑO Original Assignee Giambruno Marono Juan Manuel Priority date (The priority date is an assumption and is not a legal conclusion. Google Patents WO2002011789A1 - Artificial intracavitary ventricle The number of risks which are uninsurable becomes smaller and smaller.WO2002011789A1 - Artificial intracavitary ventricle Diagnostic therapeutic progress increasingly allows valuable insurance cover to be granted to formerly uninsurable risks, a group which is particularly in need of, and re quires, life insurance cover. Among the broad and varied data available, the insurance problem of cancer and ma lignant diseases of the haematopoietic system were extensively dealt with for the first time. This mutual engagement and en richment has again distinctly manifested itself in the scientific program of the 13th Con gress of Life Assurance Medicine held in Madrid. On the other hand, life insurance medicine has been able to pro vide valuable statistical data for long-term prognosis which have become an essential part of the daily medical practice and prognostic appraisal. On the one hand, the diagnostic therapeutic knowledge of clinical medical science forms the tools of the insurance medical adviser for the evaluation of life insurance applications. Today, the integration of life insurance medicine into the framework of general medicine goes without saying.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |